Another Possible Option for HER2-Mutated Non-Small Cell Lung Cancer

(MedPage Today) -- More than half of patients with treatment-refractory HER2-positive non-small cell lung cancer (NSCLC) responded to an anti-HER2 antibody-drug conjugate, data from a preliminary trial showed.
Fifty of 91 patients responded to...